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Abstract
The origins of the discovery of the “Complement System” date from the second half of 
the nineteenth century. The official paternity of the Complement System is attributed 
to Jules Bordet. The complement system can be activated through three major path-
ways. The classical pathway, the alternative pathway, and the lectin pathway converge 
in a common final lytic pathway. Hereditary angioedema (HAE) due to C1-inhibitor 
(C1-INH) deficiency (C1-INH-HAE) was first described by Robert Graves in his clini-
cal lectures. The autosomal dominant pattern of HAE was recognized by Sir William 
Osler. The pathophysiologic basis of C1-INH-HAE as a deficiency of a plasma inhibi-
tor was discovered in the early 1960s. In 1986, the C1NH gene was identified, which 
encodes the C1-INH protein. Although the possible relationship between angioedema 
and estrogens in women was described as early as 1986, it was not until the first decade 
of the twenty-first century when several series of patients with HAE were described 
with normal levels of the fractions of the complement system. In the last decade, several 
drugs have been approved and marketed in Europe, in the United States, and in other 
countries, contributing to the improved management of C1-INH-HAE and patient’s 
quality of life.
Keywords: acquired angioedema, angioedema, bradykinin, c1 inhibitor, complement 
system, factor XII, hereditary angioedema, hereditary angioedema with mutation in F12 
gene, history, immunodeficiency
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1. Introduction
The origins of the discovery of the “Complement System” date from the second half of the 
nineteenth century. The official paternity of the Complement System is attributed to Jules 
Bordet. The complement system can be activated through three major pathways. The classical 
pathway, the alternative pathway, and the lectin pathway converge in a common final lytic 
pathway. This chapter describes the historical discovery of biochemistry pathways implicated 
in the pathophysiology of bradykininergic angioedema (BK-AE).
2. Historical review of the Complement System
The origins of the discovery of the “Complement System” date from the second half of the 
nineteenth century. In that era, the works of Louis Pasteur (1822–1895), Robert Koch (1843–
1910) [1], and Joseph Lister (1827–1912) [2] contributed to the knowledge needed to consider 
many microorganisms as producers of lethal effects in humans. It was obvious that the human 
body, despite being constantly exposed to microorganisms, successfully overcame their 
assaults, discovering that many of them were destroyed in the blood, one of whose effector 
systems of defense was the “complement system” [3] (Figure 1).
Taube and Gscheidlen made one of the first observations that the blood of various mammals 
possessed bactericidal activity [4]. These authors injected microorganisms in the bloodstream, 
sampling at 24 and 48 hours while preserving them aseptically. Even months after storage, 
bacterial multiplication was not observed. Wyssokowitsch [5] and von Fodor [6, 7] repeated 
the experiment, injecting microorganisms in the blood of mammals, noting that within min-
utes there were no viable organisms; they thought that they had been cleared by the blood 
cells. Metschnikoff [8] found phagocytes that engulfed and destroyed microorganisms, but 
soon discovered that blood cells were not solely responsible. Grohmann [9] was the first sci-
entist who discovered that in vitro plasma (cell-free) was capable of lysing bacteria and fungi.
Nuttal [10], in experiments similar to those conducted previously by Wyssokowitsch [5] and 
von Fodor [6, 7], observed morphological changes in microorganisms (anthrax bacillus) that 
had escaped phagocytosis, concluding that they had been damaged by a noncellular process. 
After inoculating defibrinated sheep blood with bacteria, the bactericidal activity was pre-
served both in vivo and in vitro, but disappeared if the blood was heated to 45°C or was stored 
for several days at room temperature. A year later, Buchner [11, 12] reported that fresh serum 
was able to lyse bacteria, but if heated for 30 minutes at 55°C, this capacity was lost. He also 
found that the dialysis of fresh serum against water at 0°C for 18–36 hours abolished the lytic 
activity, but there was no loss when dialyzed against bicarbonate buffer containing 0.75–0.8% 
NaCl. He called fresh factor serum with bactericidal activity “alexina,” concluding that it was 
due to proteins with enzymatic activity.
Pfeiffer and Issaeff [13] reported that the activity of alexina was due to the joint action of spe-
cific antibodies and specific serum factor. In their experiment, the blood of guinea pigs that 
recovered from cholera infection protected normal guinea pigs if they were injected alexina 
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Figure 1. Historical review of the Complement System (from 1850 to 1930) [3].
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mixed with live bacteria. In vitro data showed that vibrios were eliminated only by fresh 
immune serum, but not by heat-inactivated immune serum. Protection against cholera pres-
ent during injections of heat-inactivated immune serum was due to the antibody. Therefore, 
bacterial lysis was due to the association of the antibody plus complement. Bacteriolytic 
ability of serum from animals immunized with a particular microorganism was higher than 
that of animals immunized against this microorganism.
The official paternity of the Complement System is attributed to Jules Bordet, who performed 
the critical experiments that identified the “complement system” in 1894 [14, 15]. Bordet 
[16, 17] showed that increased immune serum bactericidal activity was due to the action of 
two factors [3]:
(a) Thermostable factor increased by immunization, specifically reacting with the microor-
ganism used to immunize.
(b) Thermolabile factor present in normal and immune sera, nonspecific (at least in the way 
the thermostable factor was). Bordet quickly identified such a factor with the bactericidal 
activity or alexina described by Buchner [11, 12]. He was also able to lyse erythrocytes 
sensitized with specific antibodies against erythrocyte antigens.
Ferrata [18] showed that the complement consisted of several serum factors that could be 
separated by physicochemical means, but it was Brand [19] the following year who best char-
acterized both fractions [3]:
(a) He called the activity in the precipitate (euglobulins) “mid-piece” because he found that 
it acted after the antibody (front-piece) would bind to the cell (RBC).
(a) He called the activity in the supernatant (pseudo-globulins) “end-piece” because it acted 
only after the “mid-piece” had acted.
(b) Interaction of erythrocytes with the antibody, mid-piece, and end-piece, in that order, 
produced hemolysis.
Brand’s works established a number of assumptions:
(a) The action of the complement is sequential.
(b) An intermediate product as a function of hemolysis was generated.
Both the mid-piece and the end-piece are temperature sensitive.
2.1. Historical development of the classical complement pathway
Ritz [20] and Coca [21] were the first to demonstrate the existence of a third component other 
than the mid- and end-piece following observation of the destructive effect of cobra venom on the 
complement [3] (Figure 2). Coca treated fresh serum with yeast, concluding that the third compo-
nent was capable of combining with yeast and he called it C′3. Gordon et al. [22] showed a fourth 
component, which he called C′4 when observing that the ammonium destroyed a thermostable 
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Figure 2. Historical review of the discovery of the Complement System (from 1930 to 1985) [3].
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factor from serum other than C′3 (the mid-piece was called C′1 and the end-piece was renamed 
C′2). It should be noted at this point that C′1 and C′2 do not correspond to the current fractions 
C1 and C2, since both constitute the full complement including C′3 and C′4. Ueno [23] established 
the order of performance of the components known up to that time. Pillemer [24] managed to 
separate the four serum fractions into different components and set the activation sequence C′1, 
C′4, C′2, and C′3. It was not until the early 1960s, once chromatographic methods were developed, 
that the various components could be purified. Nelson [25, 26] showed that in reality the third 
component C′3 was formed by at least six factors (C′3c, C′3b, C′3e, C′3f, C′3a, and C′3d). Having 
established that these were proteins not related to C′3 acting at a later stage, he called them C′5, 
C′6, C′7, C′8, and C′9, respectively. As of 1968, World Health Organization (WHO) annulled the 
symbol “′” leaving it currently C1, C2, and so on.
2.2. Historical development of the alternative complement pathway
The heavy reliance of the study of the classical complement pathway using erythrocytes sen-
sitized with antibodies for activation did not even consider the possibility of activation by 
other substances [3]. However, since the early twentieth century, there were data suggesting 
that it was possible to lyse erythrocytes with cobra venom without antibodies and with the 
participation of various components other than those of the classical pathway. Pillemer [27] 
was the father of the discovery of the alternative pathway upon describing a protein or a new 
component called “properdin,” which when absent diminished the bactericidal potency of 
serum against certain bacteria.
2.3. Historical development of the final common lytic complement pathway
Green et al. [28] suggested that the cytolysis mediated by complement involved the pro-
duction of pores in the cell membrane on the grounds that large molecules (dextrans and 
albumin) prevented cell lysis when present in high concentration in the reaction medium; 
on the contrary, but small molecules did not [3] (Figure 2). Cell rupture was thought to be 
due to a colloid-osmotic swelling process that finally finished by lysing the cell. Borsos et al. 
[29], with the use of electron microscopy, visualized ultrastructural lesions etched into cell 
membranes, showing that the lesions were associated with the cytolytic complement activity. 
Lachman [30] showed that the five terminal components C5, C6, C7, C8, and C9 were neces-
sary and sufficient to cause such lesions. Haxby [31] and Kinsky [32] were the first to demon-
strate that the lipid bilayer was the target of the “membrane attack complex” (MAC), noting 
that C5-C9 directly damaged the integrity of the bilayer without any enzymatic activity. 
Mayer [33] formulated the “donut hypothesis” where cell damage is achieved through the 
formation of a structure described as a donut, forming stable transmembrane pores. Lysis 
would be explained by the osmotic difference between the exterior and the interior cell 
through the transmembrane channel. Bhadki [34] and Podack [35] observed that the MAC 
was due to C5-C9 multimolecular assembly. Bieseker [36] initially postulated a dimeric struc-
ture (C5-9)2, but Bhakdi [37] suggested a monomeric complex with the same structure as 
the complex SC5b-9 (“S” was one of the proteins that control the MAC). The C9 alone forms 
complexes structurally similar to the full MAC [38].
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3. Historical review (from C1 inhibitor to bradykinin)
Hereditary angioedema (HAE) due to C1-inhibitor (C1-INH) deficiency (C1-INH-HAE), also 
known as “non-allergic angioneurotic edema,” “AE without urticaria,” or “Osler’s hereditary 
edema” is a potentially fatal clinical entity, which in recent years has become an example to be 
followed because of the great progress made from the union of researchers, physicians, and 
patient associations worldwide (Figure 3).
It was first described in 1843 by Robert Graves in his clinical lectures. In 1882, Heinrich 
Quincke documented some cases of acute, circumscribed edema, involving two generations 
of the same family and coined the term angioneurotic edema [39]. Subsequently, Sir William 
Osler in 1888 first described in detail an inherited form of angioedema (AE) [40], from which 
in 1917 the hereditary type was identified [41]. The disease was defined biochemically in 1963 
by Donaldson and Evans [42], as an absence of serum inhibitor of the first component of the 
complement. Dating from 1972 is the first case of acquired angioedema due to C1 inhibitor 
deficiency (C1-INH-AAE) in lymphosarcoma [43].
The main symptom of C1-INH-HAE is the attack of AE, the laryngeal location being the most 
serious. Landerman [44] reviewed all the medical literature published between 1888 and 
1962 and found 28 publications of more than one case of death from fatal laryngeal attacks in 
more than one family with C1-INH-HAE. The total number of deaths due to C1-INH-HAE 
was 92.
In 1960, Spaulding demonstrated the efficacy of methyl testosterone in the treatment of 
C1-INH-HAE in a family [45]. In 1976, a double-blind placebo-controlled trial demonstrated 
the efficacy of danazol for the treatment of C1-INH-HAE [46]. It was then when stanozolol, 
another attenuated androgen, started to be used [47].
In 1968, the first case of C1-INH-HAE successfully treated with epsilon-aminocaproic acid 
(EACA) was published [48], although it was not until 1972 when the efficacy of anti-fibrinolytic 
agents (AFs), EACA, and tranexamic acid was demonstrated in double-blind clinical trials 
[49, 50]. AFs are reserved for those patients who cannot tolerate attenuated androgens or pres-
ent contraindications for their administration.
An article published in 1973 described for the first time the administration of concentrated 
C1-INH (pdC1INH), partially purified from a mixture of human plasma, in two patients 
[51]. Previously, replacement therapy in patients with C1-INH-HAE in the attack phase 
had been attempted with fresh-frozen plasma [52], which was abandoned later because of 
the risk of viral transmission, although it was still used in case of pdC1INH being unavail-
able [53].
In the USA, two double-blind placebo-controlled clinical trials had been conducted with pdC1INH, 
which had proven its efficacy and safety [54]; however, the Food and Drug Administration (FDA) 
had not yet approved its use in the 2000s. At that time, Berinert-P® (Behring, Marburg, Germany) 
was commercialized in Germany and a few European countries [55] and was available in Spain, 
where it was imported through the Foreign Medicines service [56].
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In 1986, the C1NH gene was identified (Gene Bank X54486; Swiss-Prot P05155), which encodes the 
C1INH protein, also called SERPING1, located on chromosome 11 subregion q11-q13.1 [57–59].
Although the possible relationship between AE and estrogens in women was described as 
early as 1986 [60], it was not until the first decade of the twenty-first century when several 
series of patients with HAE were described with normal levels of the fractions of the comple-
ment system [61, 62]. It was originally called HAE type III [62]. Finally, a mutation was found 
in F12 gene in some of the families [63–65].
Initially, C2-kinin, a vasoactive peptide generated by cleavage of the C2b fragment was 
thought to be involved in angioedema formation in C1-INH-HAE [66].
In 1998, there was growing support for another hypothesis in the generation of AE. It argued 
that BK was the most important mediator in the development of AE [67] and had been proven 
through clinical, in vitro studies and experiments in an experimental model of C1INH-
deficient transgenic mice [68]. In 2002, a transgenic mouse with C1 inhibitor deficiency was 
developed by Professor Davis [69].
Figure 3. Historical review of angioedema due to C1-inhibitor deficiency.
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In the last decade, several drugs have been approved and marketed in Europe, in the United 
States, and in other countries, contributing to improved management of C1-INH-HAE and 
patient’s quality of life.
First, icatibant acetate (Firazyr®, Shire HGT, Zug, Switzerland) [70, 71], a bradykinin B2 recep-
tor blocker, was approved by the European Medicines Agency (EMA) in 2008 for the treat-
ment of acute AE attacks in adult patients with C1-INH-HAE [72] and was marketed in Spain 
in March 2009.
In 2008, a new C1-esterase inhibitor formulation, Cinryze®, was approved by FDA for the 
long-term prophylaxis of C1-INH-HAE [73]. This drug incorporated a nanofiltration step as 
an extra safety procedure to reduce the transmission of enveloped and nonenveloped viruses 
and possible prions [74, 75] and had been shown to be effective in reducing the number of 
AE attacks per month [76, 77]. In 2011, the European Medicines Agency (EMA) approved the 
marketing of Cinryze® for long-term prophylaxis, but also for short-term prophylaxis and 
treatment of acute AE attacks in adults and adolescents with C1-INH-HAE [78].
Berinert®, which had been marketed in Germany in 1985, was approved in 2008–2009 in dif-
ferent European countries through a mutual recognition agreement for the treatment of acute 
AE attacks in children and adults with C1-INH-HAE. Later, it also incorporated the nano-
filtration step and it was approved by the EMA for short-term prophylaxis in children and 
adults in 2013 [79]. In 2009, FDA approved Berinert® for the treatment of acute abdominal and 
facial AE attacks in adolescents and adults with C1-INH-HAE [80].
In December 2009, Ecallantide (DX-88, Kalbitor®, Dyax Corp, currently part of Shire HGT), a 
kallikrein inhibitor, was approved by the FDA for the treatment of acute AE attacks in patients 
>16 years with C1-INH-HAE [81]. It was later approved for adolescents (2014).
A recombinant C1 inhibitor (rhC1INH) (Ruconest®, Pharming Technologies BV®, Leiden, The 
Netherlands) produced in transgenic rabbits [82] was approved by EMA in 2010 for the treat-
ment of acute AE attacks in adult patients with C1-INH-HAE [83]. It was in 2014 when the 
FDA approved it for the same indication by FDA [84].
Some European centers have developed training programs for self-administration of intrave-
nous and subcutaneous specific drugs for the treatment of C1-INH-HAE [85–90].
The development of new drugs or new uses for old drugs changed the therapeutic approach 
in C1-INH-HAE in the last decade. However, the development of new drugs will even alter 
more therapeutic landscape for C1-INH-HAE in the next years.
4. Historical review (from C1 inhibitor to coagulation factor XII)
In hereditary angioedema (HAE) with mutation in F12 gene (FXII-HAE), symptoms are simi-
lar to C1-INH-HAE, there are no abnormalities in the C1NH gene and antigenic and functional 
C1INH, C1q and C4 are usually within the normal range [91]. The final common mediator is 
thought to be bradykinin (BK). The history of the description of nC1-INH-HAE can be seen 
in Figure 4.
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Figure 4. Historical review of angioedema type III.
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In 2000, Binkley et al. [92] analyzed the family tree of eight women from three different gen-
erations noting that AE episodes were triggered by estrogen treatment (OCPs, hormone 
replacement therapy in menopause) or by pregnancies, the onset being at 14–21 days after 
conception, and at 7–14 days after the initiation of hormone replacement therapy. Börk et 
al. [93] described simultaneously a series of 36 women with angioedema with functionality 
conserved in the different fractions of the complement system (including C1 inhibitor), and 
who worsened in relation to situations of increased estrogens. Bork et al. [93] proposed to call 
this new AE type as HAE type III. Simultaneously, Marcos et al. [94] described in the XXII 
National SEAIC Congress the first family case in Spain, data that would be extended over the 
years [95]. One year later, Martin et al. [96] contributed data regarding the transmission of 
“HAE type III” in France.
Boulliet et al. [97] reported that increased levels of estrogen in healthy women have pro-
duced a reduction of C1INH, which entailed an increase in amidolytic FXII activity. Dewald 
et al. analyzed 20 unrelated women with HAE without C1INH deficiency, finding two muta-
tions in the F12 gene in the second position of the ACG codon, corresponding to the residual 
amino acid 309; mutation I (five patients) 1032C>A; Thr309Lys; and mutation II (1 patient) 
1032C>G; Thr309Arg (Figure 4). This mutation was not found in 145 healthy controls. Later, 
these authors extended the study to five families with 20 symptomatic patients and 10 asymp-
tomatic family members (eight men and two women), which showed the presence of one of 
the two mutations [98]. Cichon et al. [99] studied a family proving that the increased amido-
lytic enzymatic activity of FXII in women produced an increase in the production of kinins. A 
year later, Martin et al. [100] studied four generations of one family with eight members who 
were carriers of the F12 gene 1032C>A mutation (four symptomatic and four asymptomatic), 
noting that in women symptoms were triggered or exacerbated by estrogens, whereas in men 
the symptoms were milder.
Börk et al. [101] described 35 symptomatic women from 13 different families with FXII-
HAE (with proven mutations p.Thr309Lys/p.Thr309Arg). Triggers were taking OCPs 
(17 women) and pregnancy (3 women). A symptomatic exacerbation occurred after tak-
ing OCPs (8 women), pregnancy (7 women), hormone replacement therapy with estro-
gen (3 women), taking ACE inhibitors (2 women) and taking type 1 ACE receptor blocker 
(1 woman). pdC1INH was effective as the treatment of acute AE attacks (6 women) and 
progestogens (8 women), danazol (2 women), and tranexamic acid (1 woman) were used as 
prophylactic treatment.
Börk et al. proposed to use FXII-HAE to name those cases of nC1-INH-HAE with a mutation 
in F12 gene and unknown-HAE (U-HAE) to those without a known mutation [101].
The series with the largest number of hereditary (related to estrogen) (HAE type III) corre-
sponds to Börk et al., who described 69 patients from 23 unrelated families with HAE-FXII, 
and 196 patients with U-HAE [102].
An increase in FXII amidolytic activity was initially described as the cause of activation of 
contact system and the final release of bradykinin with the consequent angioedema in FXII-
HAE [99], although other authors could not confirm this. Recently, another study has shown 
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that the different mutations in exon 9 of F12 gene found in FXII-HAE produce an increase in 
FXII activability by plasmin [103].
In Spain, several studies have been published focusing on FXIII-HAE: Serrano et al. [104] (six 
cases; two of them women from the same family) and Prieto et al. [105] (four generations of 
the same family with mutation 1032C>A; Thr309Lys; three symptomatic women, one male 
asymptomatic carrier).
Baeza et al. [106] described a nonatopic 27-year-old Arab woman from Morocco with a clinical 
diagnosis of hereditary angioedema type III and the p.Thr328Lys mutation. Icatibant acetate 
was prescribed for compassionate use.
Gómez-Traseira et al. [107] describes 20 cases (11 females and 9 males on a large 3-generation 
Spanish family). The p.Thr309Lys mutation was detected in five female patients who had a 
phenotypic variant in which AE was exclusively precipitated by high estrogen levels and in 
six asymptomatic relatives.
Piñero-Saavedra et al. [108] described p.Thr309Lys mutation in 35 individuals (80% females) 
from 9 unrelated families. In this prospective observational cohort study, 16 females (44% 
estrogen dependent, 56% estrogen sensitive) were clearly symptomatic. Also, two poly-
morphisms (XPNPEP2 c-2399A and the ACE insertion/deletion) were detected in 17% of 
patients.
The University Hospital in Grenoble is a reference center for the study of FXII-HAE in France. 
As a result of this, Vitrat-Hincky et al. [109] published a retrospective analysis (for the years 
2000–2009) with 26 patients, which included four symptomatic men).
Duan et al. [110] not only confirmed the F12 gene mutation (gene-codifying coagulation factor 
XII) in women of the same family but also provide certain polymorphisms in the genes encod-
ing aminopeptidase P (APP) and angiotensin-converting enzyme (ACE). It highlights the role 
of the BK-catabolizing enzymes in the pathogenesis of angioedema.
Börk et al. [111] described a new mutation in the F12 gene (deletion of 72 base pairs 
c.971_1018+24del72*). More recently, Kiss et al. [112] described a new mutation consisting in 
the duplication of 18 base pairs (c.892_909dup) causing the repeated presence of 6 aa (p.298-
303) in the same region of FXII to those described above.
Grumach et al. [113] report two Brazilian FXII-HAE families segregating the mutation c.983 
C>A (p.Thr328Lys). In each family, one patient with a homozygous mutation was found. The 
homozygous FXII-HAE mutation status leads to a severe phenotype in females and males, 
and to an increased risk of manifest symptoms in the latter.
In terms of treatment, there is no approved drug for the treatment of nC1-INH-HAE, 
either FXII-HAE or U-HAE. The pdhC1INH has been used in the acute attack of AE in 
some cases of FXII-HAE [102, 114, 115]. More recently, icatibant acetate was effective but 
also used off-label as this indication is not reflected in the product’s prescribing informa-
tion [115].
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